Tivic Health Files New Patents For TLR5 Agonists In Advanced Cancer Therapy And Optimized Vagus Nerve Stimulation Device

New Biologics Patent Application Covers Potential Applicability of TLR5 Agonists to Improve Outcomes for Late-stage Cancer Therapies; Bioelectronic Patent Covers Optimized ncVNS Device Specifications

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, today announced it is expanding its intellectual property portfolio with the recent filing of two additional patent applications with the United States Patent and Trademark Office.

The first application applies to Tivic's TLR5 agonist portfolio, which includes Entolimod and Entolasta. The patent titled "Immunomodulatory Pathway Modifying Agents and Uses of Same for Cancer Therapy" relates to the potential newly identified applications of TLR5 agonists such as Entolimod and Entolasta, as an adjunctive therapy to improve the effectiveness of T-cell, NK-cell and other immuno-oncology cell-based therapies for advanced-stage cancer. Patients receiving such therapies are often immunocompromised from earlier treatment regimens, and TLR5 agonists, used as an adjunctive therapy, may enhance outcomes. The second application, "Vagus Nerve Electrical Stimulation System," covers device parameters that have been shown to have optimal impact on autonomic system activity via non-invasive vagus nerve stimulation.